Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, California, USA.
Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, Oregon, USA.
Mol Cell Biol. 2018 Feb 27;38(6). doi: 10.1128/MCB.00463-17. Print 2018 Mar 15.
The transcription factor gene is important in breast cancer, and its mRNA is maintained at a high level even in the absence of gene amplification. The mechanism(s) underlying increased mRNA expression is unknown. Here, we demonstrate that mRNA was stabilized upon estrogen stimulation of estrogen receptor-positive breast cancer cells via SRC-dependent effects on a recently described RNA-binding protein, IMP1 with an N-terminal deletion (ΔN-IMP1). We also show that loss of the tumor suppressor p53 increased mRNA levels even in the absence of estrogen stimulation. However, in cells with wild-type p53, SRC acted to overcome p53-mediated inhibition of estrogen-stimulated cell cycle entry and progression. SRC thus promotes cell proliferation in two ways: by stabilizing mRNA and by inhibiting p53 function. Since estrogen receptor-positive breast cancers typically express wild-type p53, these studies establish a rationale for p53 status to be predictive for effective SRC inhibitor treatment in this subtype of breast cancer.
转录因子基因在乳腺癌中很重要,其 mRNA 即使在基因扩增缺失的情况下也能维持在高水平。导致 mRNA 表达增加的机制尚不清楚。在这里,我们证明了雌激素刺激雌激素受体阳性乳腺癌细胞会通过 SRC 对最近描述的 RNA 结合蛋白 IMP1 的作用(IMP1 具有 N 端缺失(ΔN-IMP1))稳定 mRNA。我们还表明,即使没有雌激素刺激,肿瘤抑制因子 p53 的缺失也会增加 mRNA 水平。然而,在具有野生型 p53 的细胞中,SRC 作用可以克服 p53 介导的对雌激素刺激的细胞周期进入和进展的抑制。因此,SRC 通过两种方式促进细胞增殖:稳定 mRNA 和抑制 p53 功能。由于雌激素受体阳性乳腺癌通常表达野生型 p53,这些研究为 p53 状态在这种乳腺癌亚型中作为有效 SRC 抑制剂治疗的预测因素提供了依据。